Is TB-500 Legal in Wisconsin? Federal Framework, Prescription Rules, and How to Get It
See the public record for TB-500
At a glance
- FDA approval / None; no approved drug contains TB-500 [1]
- FDA bulk lists / Not on FDA's lists for state-licensed pharmacies and physicians or outsourcing facilities [2][3][4]
- Advisory committee / Voted 23 July 2026 to recommend adding it to the pharmacy bulks list [7][5]
- HHS draft policy / Covers TB-500 acetate injection; filed 28 October 2026 [5][6]
- Human safety data / No exposure, toxicity or immunogenicity data found [1]
- Sport / Prohibited at all times under WADA S2.3 [8]
What TB-500 is
TB-500 is a synthetic, N-acetylated 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4, not the full-length protein. FDA found several salts and derivatives, including different active moieties, sold under the same name [1].
FDA's July 2026 review found no USP or National Formulary monograph for it, no FDA-approved drug containing it, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1].
Why no compounding list covers it
FDA says a state-licensed pharmacy or physician may compound with a bulk substance only if it meets an applicable USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's bulk list [4]. TB-500 fits none of the three. It has no monograph, is not a component of an approved drug, and appears on neither FDA's list for state-licensed pharmacies and physicians nor the separate list for outsourcing facilities [1][2][3][4].
TB-500 does appear in the 'nominated but withdrawn' table on FDA's safety-risk page, which holds substances previously in category 2 whose nominators withdrew them. Removal from category 2 was not a finding that it is safe [9].
Questions worth asking
The committee vote and the HHS draft
On 23 July 2026 the Pharmacy Compounding Advisory Committee voted in favour of adding TB-500 to the pharmacy bulks list, against FDA staff's recommendation. TB-500 is not on the list, and adding it takes formal rulemaking [7][5].
HHS filed a draft enforcement-discretion policy on 28 October 2026 naming TB-500 among six peptides and covering TB-500 acetate given by subcutaneous or intramuscular injection. Under it, HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it when the conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and the label 'This is a compounded drug product. Not for resale.' [5][6]
The notice says the draft 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it if a safety signal or product quality issue arises [5]. FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients [5].
Safety and sport
FDA found no human pharmacokinetic data for TB-500 by any route, no nonclinical toxicity studies and no immunogenicity data; its stated concern for injectable TB-500 is immunogenicity [1]. Its adverse-event database search through 26 March 2025 retrieved no TB-500 reports, and FDA found no published case reports. Safety in humans is unknown [1].
WADA lists 'Thymosin-beta4 and its derivatives e.g. TB-500' in section S2.3, prohibited at all times, on the 2026 and 2027 Prohibited Lists [8][10].
Frequently asked questions
Is TB-500 FDA-approved?
Can a compounding pharmacy make TB-500?
Did an FDA advisory committee approve TB-500?
Is TB-500 the same as thymosin beta-4?
Is TB-500 banned in sport?
References
Show all 10 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Official web page.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.